A Pilot Proof of Concept Single-Center Study of the Use of Oritavancin in Systemic Staphylococcus aureus Infections in Patients with Opioid Use Disorder
Brief description of study
The study participants will be in the study for approximately 2 months including the screening, intervention phase and the 6 weeks of follow-up time
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Staphylococcus Aureus Bacteremia | Staphylococcus Aureus Endocarditis
-
Age: - 99 Years
-
Gender: All
Updated on
30 Jan 2020.
Study ID: 831334